eukaryotic translation initiation factor 2B subunit epsilon
Senast uppdaterad 18 aug 2020
Uppfyller patientens redaktionella riktlinjer
- Ladda nerLadda ner
- Dela
- Language
- Diskussion
- Ask Patient
- Ljudversion
- Lägg till i föredragna källor på Google
Den EIF2B5 gene provides instructions for making one of five parts of a protein called eIF2B, specifically the epsilon subunit of this protein. The eIF2B protein helps regulate overall protein production (synthesis) in the cell by interacting with another protein, eIF2. The eIF2 protein is called an initiation factor because it is involved in starting (initiating) protein synthesis.
Videoval för GenesVideobibliotek
Normal function
Den EIF2B5 gene provides instructions for making one of five parts of a protein called eIF2B, specifically the epsilon subunit of this protein. The eIF2B protein helps regulate overall protein production (synthesis) in the cell by interacting with another protein, eIF2. The eIF2 protein is called an initiation factor because it is involved in starting (initiating) protein synthesis.
Under some conditions, eIF2B increases protein synthesis by helping to recycle molecules called GTP, which carry energy to the initiation factor. Under other conditions, it slows protein synthesis by binding tightly to the initiation factor, which converts the eIF2B protein into an inactive form and prevents recycling of GTP.
Proper regulation of protein synthesis is vital for ensuring that the correct levels of protein are available for the cell to cope with changing conditions. For example, cells must synthesize protein much faster if they are multiplying than if they are in a resting state.
Conditions referring to this gene or chromosome
Other names
CACH
CLE
EI2BE_HUMAN
EIF-2B
eIF-2B GDP-GTP exchange factor
EIF2Bepsilon
eukaryotic translation initiation factor 2B, subunit 5 (epsilon, 82kD)
eukaryotic translation initiation factor 2B, subunit 5 epsilon, 82kDa
LVWM
Related patient information and medicines

Patient information leaflet
Fakta om bröstcancer och riskfaktorer
What are the risk factors for breast cancer. Dr Sarah Jarvis MBE Although breast cancer can develop for no apparent reason, there are certain risk factors which increase the chance that bröstcancer will develop. /health/breast-cancer-leaflet Most cases of breast cancer occur by chance. However, breast cancer does occur more.

Patient information leaflet
Orsaker till cancer
Certain risk factors are known to increase the chance that one eller more of your cells will become abnormal and lead to cancer. How does cancer start. The body is made up from millions of tiny cells. Different parts of the body such as organs, bones, muscles, skin and blood are made up from different specialised cells. Most cells have a centre.

Patient information leaflet
Akut lymfatisk leukemi
Akut lymfatisk leukemi (ALL) is a condition where the bone marrow makes large numbers of abnormal immature lymphocytes. What is acute lymphoblastic leukaemia. Acute lymphoblastic leukaemia (ALL) is a condition where the bone marrow makes large numbers of abnormal immature lymphocytes. The immature cells are called lymphoblasts. There are.

Patient information leaflet
Hemofili
Hemofili is a rare bleeding disorder that affects your ability to make a clot. The blood contains substances called clotting factors that work with platelets to form a clot. When you injure yourself the clot stops you bleeding. Haemophilia is a condition where there is a deficiency of clotting factors, so people with this condition usually have.

Patient information leaflet
Blodproppstester
Blodproppstester är used till diagnose och assess bleeding problems and to monitor people who take warfarin or other anticoagulant medicines. You may be advised to have blood clotting tests: If you have a suspected bleeding disorder. For example, if you bleed a lot after cuts, or if you bruise easily. If you have certain liver diseases that can.

Patient information leaflet
Muncancer
Diagnosing mouth cancer Your healthcare professional may suspect mouth cancer if you have a lesion in your mouth (such as a sore, an ulcer or a lump) which has not healed for 3 wee... Dr Krishna Vakharia , 16th October 2023 The National Institute for Health and Care Excellence (NICE) has recommended that a person should receive a diagnosis or.
Vidare läsning och referenser
- eukaryotic translation initiation factor 2B subunit epsilon; MedlinePlus, National Library of Medicine.
- Dietrich J, Lacagnina M, Gass D, Richfield E, Mayer-Proschel M, Noble M, Torres C, Proschel C. EIF2B5 mutations compromise GFAP+ astrocyte generation in vanishing white matter leukodystrophy. Nat Med. 2005 Mar;11(3):277-83. doi: 10.1038/nm1195. Epub 2005 Feb 20.
- Eurekah Bioscience: Mechanism of Translation Initiation in Eukaryotes
- Fogli A, Boespflug-Tanguy O. The large spectrum of eIF2B-related diseases. Biochem Soc Trans. 2006 Feb;34(Pt 1):22-9. doi: 10.1042/BST20060022.
- Fogli A, Schiffmann R, Hugendubler L, Combes P, Bertini E, Rodriguez D, Kimball SR, Boespflug-Tanguy O. Decreased guanine nucleotide exchange factor activity in eIF2B-mutated patients. Eur J Hum Genet. 2004 Jul;12(7):561-6. doi: 10.1038/sj.ejhg.5201189.
- Li W, Wang X, Van Der Knaap MS, Proud CG. Mutations linked to leukoencephalopathy with vanishing white matter impair the function of the eukaryotic initiation factor 2B complex in diverse ways. Mol Cell Biol. 2004 Apr;24(8):3295-306. doi: 10.1128/MCB.24.8.3295-3306.2004.
- Molecular Biology of the Cell (fourth edition, 2002): The Phosphorylation of an Initiation Factor Globally Regulates Protein Synthesis
- Pavitt GD. eIF2B, a mediator of general and gene-specific translational control. Biochem Soc Trans. 2005 Dec;33(Pt 6):1487-92. doi: 10.1042/BST0331487.
- Pronk JC, van Kollenburg B, Scheper GC, van der Knaap MS. Vanishing white matter disease: a review with focus on its genetics. Ment Retard Dev Disabil Res Rev. 2006;12(2):123-8. doi: 10.1002/mrdd.20104.
- Scali O, Di Perri C, Federico A. The spectrum of mutations for the diagnosis of vanishing white matter disease. Neurol Sci. 2006 Sep;27(4):271-7. doi: 10.1007/s10072-006-0683-y.
- Scheper GC, Proud CG, van der Knaap MS. Defective translation initiation causes vanishing of cerebral white matter. Trends Mol Med. 2006 Apr;12(4):159-66. doi: 10.1016/j.molmed.2006.02.006. Epub 2006 Mar 20.
- van der Voorn JP, van Kollenburg B, Bertrand G, Van Haren K, Scheper GC, Powers JM, van der Knaap MS. The unfolded protein response in vanishing white matter disease. J Neuropathol Exp Neurol. 2005 Sep;64(9):770-5. doi: 10.1097/01.jnen.0000178446.41595.3a.
- van Kollenburg B, van Dijk J, Garbern J, Thomas AA, Scheper GC, Powers JM, van der Knaap MS. Glia-specific activation of all pathways of the unfolded protein response in vanishing white matter disease. J Neuropathol Exp Neurol. 2006 Jul;65(7):707-15. doi: 10.1097/01.jnen.0000228201.27539.50.
Artikelhistorik
Artikeln finns också på Engelska, Tyska, Spanska, Franska, Italienska, Portugisiska, Hindi, Hebreiska, Arabiska, och Svenska.
18 aug 2020 | Senaste versionen
1 Oct 2007 | Ursprungligen publicerad
Dela dina tankar eller erfarenheter med andra i vår patientgemenskaper.
Anmäl dig till Patientens nyhetsbrev
Din veckovisa dos av tydliga, pålitliga hälsoråd - skrivna för att hjälpa dig känna dig informerad, självsäker och i kontroll.
Genom att prenumerera accepterar du våra Sekretesspolicy. Du kan avsluta prenumerationen när som helst. Vi säljer aldrig dina uppgifter.

